FGF23 and chronic kidney disease: Finally, two smaller investigations highlighted that raised serum FGF-23 correlates with levels of bone metabolism-related markers and vertebral fractures in older non-dialysis patients, as well as increased insulin resistance in non-diabetic, non-dialysis stage 3–5 CKD patients [44,54], among many other potential pleiotropic effects [45].